Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with everolimus.

J J Augustine1, D E Hricik

  • 1Department of Medicine Case Western Reserve University and the Transplantation Service, University Hospitals of Cleveland, Cleveland, OH 44106, USA.

Transplantation Proceedings
|March 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abdominal Organ Transplant Center Tobacco Use Policies Vary by Organ Program Type.

Transplantation proceedings·2016
Same author

Interferon Gamma ELISPOT Testing as a Risk-Stratifying Biomarker for Kidney Transplant Injury: Results From the CTOT-01 Multicenter Study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Fever of Unknown Origin in a Kidney Transplant Recipient.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient.

Transplant infectious disease : an official journal of the Transplantation Society·2015
Same author

Cutaneous histoplasmosis in renal transplant recipients.

Clinical transplantation·2014
Same author

Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
Same journal

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
Same journal

Evaluating CMV Risk Stratification, Donor Characteristics, and Post-Transplant Outcomes in Kidney Transplant Recipients: A Retrospective Eurotransplant Center Analysis.

Transplantation proceedings·2026
Same journal

Twenty-One Years of Insights From A Single-Center Living Kidney Donation Program.

Transplantation proceedings·2026
See all related articles

Everolimus, an immunosuppressant, inhibits T-lymphocyte proliferation and offers advantages over sirolimus. It shows promise in preventing transplant rejection and allograft vasculopathy with a good safety profile.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation

Background:

  • Everolimus is a novel macrolide immunosuppressant.
  • It functions as a T-lymphocyte proliferation signal inhibitor.
  • Its mechanism is complementary and synergistic with calcineurin inhibitors.

Purpose of the Study:

  • To evaluate the efficacy and safety of everolimus in transplant patients.
  • To compare pharmacokinetic characteristics of everolimus with sirolimus.
  • To explore the potential of everolimus in preventing allograft vasculopathy.

Main Methods:

  • Pharmacokinetic analysis comparing everolimus and sirolimus.
  • Clinical assessment in kidney transplant recipients on cyclosporine-based immunosuppression.
  • Observational study in heart transplant patients.

Related Experiment Videos

Main Results:

  • Everolimus demonstrates greater bioavailability and a shorter half-life than sirolimus, enabling faster achievement of steady-state drug levels.
  • In kidney transplant patients, everolimus is associated with low acute rejection rates and a tolerable safety profile.
  • Preliminary data suggest everolimus may prevent allograft vasculopathy in heart transplant recipients.

Conclusions:

  • Everolimus is an effective immunosuppressant with favorable pharmacokinetics.
  • It offers a viable option for preventing acute rejection and potentially allograft vasculopathy in transplant patients.
  • Further research is warranted to fully elucidate its long-term benefits and safety.